Acute cardiac care & resuscitationRandomised controlled trial
Serum biomarkers of postanoxic encephalopathy in relation to ghrelin treatment. A secondary analysis of the Ghrelin in Coma (GRECO) trial
- phase 2, double-blind, randomised, placebo-controlled trial
- secondary analysis
Authors' conclusion
Acyl-ghrelin treatment during the first week after cardiac arrest was associated with less GFAP elevation in the first three days, suggesting reduced astroglial activation and/or damage. No other significant effects were found, except for S100, pTau181, and UCH-L1 on day 0, possibly indicating baseline imbalances.
Study context
- Population
- Comatose patients after cardiac arrestof 160 participants with serum samples (65 intervention)
- Participants
- 125 patients
- Comparison
- acyl-ghrelin or placebo
- acyl-ghrelinn = 65
Primary result
As reported in the abstract
day 1 estimate
0.855
day 1 p
p = 0.015
day 3 estimate
1.017
day 3 p
p = 0.0037
Further findings
Other neuro-biomarkers (neuron-specific enolase (NSE), ubiquitin carboxyl hydrolase L1 (UCH-L1), S100, neurofilament light (NfL), pTau181)
- No significant effect of acyl-ghrelin on other timepoints, except on day 0 for S100, pTau181, and UCH-L1
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Summarised from the published abstract; every number is checked against it